Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide 1.5 mg vs placebo added to basal insulin glargine in type 2 diabetes
2012-004229-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of dulaglutide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Feb 2014; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-004229-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004229-25.